Edesa Biotech to Participate in Upcoming Investor Conferences

TORONTO, ON, April 2, 2024 – Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, today announced its participation in several investor conferences in the coming weeks. The company is known for its development of host-directed therapeutics for immuno-inflammatory diseases. Edesa's management team is scheduled to attend the Mintz Conference in Toronto, Canada, on April 15, 2024, the LSX World Congress in London, UK, from April 29-30, 2024, where they will present at 4:30 pm GMT on April 29, and the RBC Capital Markets Global Healthcare Conference in New York, NY, on May 14-15, 2024.

Interested parties are invited to schedule a meeting with Edesa during these events by contacting conference organizers or the company directly at investors@edesabiotech.com. This engagement with the investment community comes at a time when the company is making significant progress in the development of its drug candidates, including EB05 for Acute Respiratory Distress Syndrome, EB06 for vitiligo, and EB01 for Allergic Contact Dermatitis.